FDA Determines Regulatory Review Period for Pfizer's Viagra Patent Extension Application

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for Pfizer's Viagra, and is publishing this notice as required by law. The determination was made due to a submission to the U.S. Patent and Trademark Office for the extension of a patent on the human drug product.